Permanent doctors say that the treatment of weight loss, “Montgro” and “Wigofi” is so effective, that they should be the first treatment of obesity “in almost all cases.”
In new directions for doctors, the European Association for the Study of Obesity praised the effectiveness of the two medicines and their great health benefits. They described them as a strong aide to slimming, and they can reduce the risk of associated complications, such as high blood pressure and type 2 diabetes, according to a report in the Daily Mail.
Studies have shown that the adults who used our right contain seedaglotide, which is the active component of my medicine, Wagofi and Osimbek, lost 14% of their bodies over 72 weeks.
As for those who consumed Terzopatid, known as Monagaru, to lose weight, they lost 20% of their bodies during the same period.
Dr. Andrea Seydin, the main author participating in the guide from the Independent University of Barcelona, said that these drugs “have radically shift in obesity care and complications.”
“Although there are many options available on the market, the seedlottide and Terzopatid are very effective, so they should be the first option in almost all cases,” she added.
These guidelines were published in the “Nature Medicine” magazine, and was prepared by an international team of experts, including contributors from the United Kingdom.
Experts analyzed current studies, and have developed an algorithm that enables doctors to advise on the best treatment for weight loss based on the patient’s weight and associated health conditions.
They concluded that the Terzepatide and the Terzopatid should be considered “preferred drugs” when the need for a “large” loss of the total body weight. When the goal is to lose weight to a lesser extent, other drugs can be considered, including Lerglotide, Naltrexone-Bubrobion, and Vintrin-Toberamite.
Chronic kidney disease
The guidelines indicate that there are increasing evidence that these injections have health benefits for a number of diseases that exceed the mere weight loss, but more studies are needed.
In summary of the algorithm, the authors say, “It is important to note that most medications were not specially evaluated to treat individual complications, which leads to gaps in our understanding of their full therapeutic capabilities. Although some benefits can be deduced based on the degree of total weight loss – given the positive effective effect of total weight loss on various complications – the direct evidence of many cases is still limited.
However, there are increasing possibilities for medicines to positively affect a wider set of complications, including chronic kidney disease, degenerative neurological disorders, ovarian cyst syndrome, some types of cancer, and mental health. “
The authors refer to complex economic considerations, which differ from one country to another, but they say, “The cost of non -treatment of obesity and the imbalance of fatty tissue functions must be taken in the early stages – which allows the development of complications and peripheral organ damage – in consideration equally in health policies and clinical decision -making.”
“This is the first working framework guided by the presence or absence of complications associated with obesity, because weight loss is not the only goal of treatment when there are complications,” said Professor Barbara McGuan, a authors of the guidelines, from the Jays Hospital Foundation and St. Thomas of the National Health Services Authority in London.
The design of the appropriate treatment for each individual is a complex task that must take into account several factors, including the severity of obesity, the presence and extent of complications, accompanying diseases, and simultaneous treatments.